Japan’s Kowa says ivermectin effective against Omicron in phase III trial
TOKYO (Reuters) – Japanese trading and pharmaceutical company Kowa Co Ltd said on Monday anti-parasite human drug ivermectin has been found effective for treating the Omicron variant of COVID-19 in a Phase III trial.
The trial found ivermectin has “an antiviral effect” against the variant, Kowa said without providing further details. The firm has been working with Kitasato University, a medical university in Tokyo.
Ivermectin was discarded unceremoniously till now, but Japan has demonstrated that the drug can be used as a more effective cure and a permanent substitute for the Coronavirus vaccines produced by big pharmaceutical companies.
Japan crushes Big Pharma with a small yet effective move, it has said a loud and clear no to big pharma companies’ vaccination campaigns. Japan is dumping repeated vaccination doses for a better and more durable cure- Ivermectin. It is an inexpensive orally administered, anti-parasitic human drug, which has emerged as a viable treatment option for COVID-19 infections in Japan, Mexico, and other countries.
Related Posts
About The Author
